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Abstract 
  
Background 
The  ‘Surviving  Sepsis’  Campaign  guidelines  recommend  the 
use of dopamine or noradrenaline as the first vasopressor in 
septic shock. However, information that guides clinicians in 
choosing  between  dopamine  and  noradrenaline  as  the  first 
vasopressor in patients with septic shock is limited.  
Objective   
This article presents a review of the literature regarding the 
use of dopamine versus noradrenaline in patients with septic 
shock. 
Results 
Two  randomised  controlled  trials  (RCT)  and  two  large 
prospective cohort studies were analysed. RCT data showed 
dopamine was associated with increased arrhythmic events. 
One cohort study found dopamine was associated with higher 
30-day mortality. The other cohort study found noradrenaline 
was associated with higher 28-day mortality. 
Discussion 
Data on the use of dopamine versus noradrenaline in patients 
with  septic  shock  is  limited.  Following  the  recent  SOAP  II 
study, there is now strong evidence that the use of dopamine  
 
 
 
 
 
 
 
 
 
 
 
 
in  septic  shock  is  associated  with  significantly  more 
cardiovascular  adverse  events,  compared  to 
noradrenaline.  
Conclusion 
Noradrenaline should be used as the initial vasopressor in 
septic  shock  to  avoid  the  arrhythmic  events  associated 
with dopamine.  
Key Words 
Dopamine, noradrenaline, norepinephrine, sepsis, septic 
shock, vasopressor  
 
Background 
The  2008  ‘Surviving  Sepsis  Campaign  International 
Guidelines’  define  severe  sepsis  as  acute  organ 
dysfunction  (e.g.  hypotension,  decreased  urine  output 
and  elevated  creatinine)  secondary  to  infection.
1  Septic 
shock is defined as severe sepsis with hypotension that is 
refractory to fluid resuscitation.
1 Septic shock needs to be 
recognised  and  treated  immediately  as  it  carries  high 
mortality.  To  maintain  adequate  organ  perfusion,  the 
administration of a vasopressor is required. The Surviving 
Sepsis  Campaign  recommends  either  noradrenaline  or 
dopamine as the first choice vasopressor agent to correct 
hypotension in septic shock.
1  
 
Dopamine  is  the  precursor  for  noradrenaline  in  the 
sympathetic  nervous  system.
2  At  doses  of  1–
2µg/kilogram/minute,  it  mainly  acts  on  vascular 
dopamine-1 receptors causing selective vasodilatation. At 
doses between 5 and 10 µg/kilogram/minute, dopamine 
also acts on beta-1 adrenergic receptors in the heart to 
increase cardiac output by increasing stroke volume and 
heart  rate;  at  doses  above  10  µg/kilogram/minute,  it 
mainly acts on vascular alpha-1 adrenoceptors to cause 
vasoconstriction,  increasing  the  systemic  vascular 
resistance.
3 The adverse effects of dopamine include the 
suppression  of  prolactin,  thyroid  stimulating  hormone 
and luteinising hormone.
4 It was previously believed that 
low  dose  dopamine  in  critically  ill  patients  was  reno-
protective by increasing renal blood flow. This has been 
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disproven  by  RCT  data:  low  dose  dopamine  does  not  offer 
significant  protection  against  renal  failure  compared  to 
placebo.
5  
 
Endogenously,  noradrenaline  is  released  from  the  nerve 
terminal of post-ganglionic sympathetic neurons.
2 It acts on 
alpha-1 adrenoceptors to cause vasoconstriction.
2 It also has a 
weaker  action  on  beta-1  adrenoceptors.
3  However, 
noradrenaline’s action on beta-1 adrenoceptors is cancelled 
out by a reflex bradycardia in response to the increased blood 
pressure.
3  Therefore,  overall,  the  heart  rate  remains 
unchanged.  Compared  to  dopamine,  noradrenaline  causes 
less tachycardia, and less tachyarrhythmia.  
 
In  clinical  practice,  there  is  no  clear  guideline  that 
recommends  when  dopamine  versus  noradrenaline  should 
be used in septic shock. This prompted a literature review on 
the use of dopamine versus noradrenaline in septic shock. 
 
Method/Search strategy 
A  literature  search  was  conducted  using  MEDLINE  (via  an 
EBSCOhost® search platform; publication date: 1962–2010). 
The  terms  searched  were  ‘shock’,  ‘dopamine’  and 
‘noradrenaline’. These topics were matched by MEDLINE to 
the  medical  subject  headings  (MeSH)  terms  ‘shock’, 
‘dopamine’  and  ‘norepinephrine’.  Forty-six  results  yielded 
from  a  combined  search  of  ‘shock’,  ‘dopamine’  and 
‘norepinephrine’. The inclusion criteria were: if the studies 
were  large  prospective  cohort  studies,  RCTs  or  systematic 
meta-analyses,  and  written  in  English.  The  articles  were 
excluded if they were case reports or case series, or written 
in  a  language  other  than  English.  Of  these,  four  relevant 
studies were identified and included in the literature review: 
two  were  RCT  and  two  were  large  prospective  cohort 
studies. 
 
Results 
RCTs 
The Sepsis Occurrence in Acutely Ill Patients II (SOAP II) study 
was  a  multi-centre  RCT  that  compared  dopamine  and 
noradrenaline as the initial vasopressor in the treatment of 
shock.
6 A total of 1,679 intensive care unit (ICU) patients with 
shock  were  randomised  for  treatment  with  dopamine 
(n=858) or noradrenaline (n=821) (Table 1).
6 All patients older 
than  18  years  of  age  who  required  a  vasopressor  for  the 
treatment of shock were included. The exclusion criteria were: 
•  under 18 years of age; 
•  already  received  a  vasopressor  for  more  than 
four hours during shock; 
•  serious arrhythmia: e.g. rapid atrial fibrillation or 
ventricular tachycardia; 
•  brain dead. 
The parameters of shock used in the study were: 
•  mean arterial pressure <70mmHg; or 
•  systolic  blood  pressure  <100mmHg  despite 
adequate fluids; and 
•  signs of tissue hypoperfusion, such as:  
￿  altered mental state; 
￿  mottled skin; 
￿  urine output <0.5mL/kg for one hour; 
￿  lactate>2mmol/litre. 
 
The  patients  were  classified  according  to  the  type  of 
shock:  septic  shock  (n=1044,  62.2%),  cardiogenic  shock 
(n=280, 16.7%) and hypovolaemic shock (n=263, 15.7%). 
 
Table 1: Levels of evidence and summary of results of 
the studies analysed in the literature review 
 
When blood pressure could not be maintained at the pre-
specified  maximal  dose  of  vasopressor 
(20µg/kilogram/minute  for  dopamine;  or 
0.19µg/kilogram/minute  for  noradrenaline),  open-label 
noradrenaline, adrenaline or vasopressin could be added. 
There was no significant difference in the death rate at 28 
days  (52.5%  in  the  dopamine  group;  48.5%  in  the 
Study  Evidence  Patient 
numbers 
Outcome 
measures 
Intervention  Results 
SOAP II 
study, 
2010
6  
RCT  1679: 858 in 
dopamine 
group; 821 in 
noradrenaline 
group 
First outcome 
measures: 
mortality at 
28 days after 
randomisation 
 
Second 
outcome 
measures: 
number of 
days without 
organ support 
and adverse 
events 
Either 
dopamine or 
noradrenaline 
as 1
st line 
vasopressor 
 
 
No 
significant 
difference 
in morality 
at 28 days 
 
Dopamine 
associated 
with more 
arrhythmic 
events 
Patel et 
al., 
2010
7 
RCT  252: 134 in 
dopamine 
group; 118 in 
noradrenaline 
group 
First outcome 
measures: 
mortality at 
28 days after 
randomisation 
 
Second 
outcome 
measures: 
organ 
dysfunction, 
hospital and 
ICU length of 
stay and 
adverse 
events 
Either 
dopamine or 
noradrenaline 
as first line 
vasopressor 
 
No 
significant 
difference 
in mortality 
at 28 days 
 
Dopamine 
associated 
with more 
arrhythmic 
events  
SOAP 
study, 
2006
8 
Cohort 
study 
1058: 375 in 
dopamine 
group; 683 in 
non-
dopamine 
group 
ICU/hospital 
mortality 
rates and 30-
day survival  
 
 
Not applicable  Dopamine 
group had 
higher ICU 
and 
hospital 
mortality 
rates, 
diminished 
30-day 
survival 
SACiUCI 
study, 
2009
9 
Cohort 
study 
458: 50.5% 
received 
dopamine; 
73% received 
noradrenaline 
Hospital 
mortality rate 
and 28-day 
survival 
Not applicable  Noradrenal
ine group 
had 
reduced 
28-day 
survival  Australasian Medical Journal [AMJ 2011, 4, 10, 571-574] 
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noradrenaline group; P=0.10). There were significantly more 
arrhythmic  events  in  the  dopamine  group,  mostly  atrial 
fibrillation (24.1% versus 12.4% in the noradrenaline group; 
P<0.001).  A  subgroup  analysis  showed  that  dopamine 
increased mortality at 28 days in cardiogenic, but not septic or 
hypovolaemic shock, when compared to noradrenaline.   
 
The study by Patel et al. 2010 was a single centre RCT with a 
similar study design to SOAP II.
7 It involved a smaller number 
of patients with septic shock (n=252); 134 out of 252 patients 
were  randomised  to  dopamine,  and  118  patients  were 
randomised  to  noradrenaline.  It  found  no  significant 
difference  in  mortality  at  28  days  (50%  in  the  dopamine 
group; 43% in the noradrenaline group; P=0.282). There was a 
significantly  increased  incidence  of  arrhythmia  in  the 
dopamine  group  (19.4%  versus  3.4%  in  the  noradrenaline 
group). 
 
Cohort studies 
The  SOAP  study  was  a  multi-centre,  cohort  observational 
study investigating dopamine use on the outcome of shock.
8 A 
total of 1,058 patients with shock were studied, of which 462 
patients had septic shock. This cohort came from 3,147 ICU 
patients. All patients older than 15 years were included in the 
study. Those who  stayed in  the ICU less than 24 hours  for 
routine post-operative observations and patients with burns 
were excluded. Patients were followed up until death, until 
hospital discharge, or for 60 days. Patients in the dopamine 
group were found to have higher ICU (42.9% versus 35.7%; 
P=0.2)  and  hospital  (49.9%  versus  41.7%,  P=0.01)  mortality 
rates.   
 
The Sepsis Adquirida na Comunidade e internada em Unidade 
de  Cuidados  Intensivos  (SACiUCI)  study  was  also  a  multi-
centre, cohort observational study.
9 A total of 897 consecutive 
patients  admitted  to  ICU  with  community-acquired  sepsis 
were studied; 458 patients had septic shock. All patients 18 
years of age or older were included. They were followed up 
until death or hospital discharge. A total of 73% of patients 
received  noradrenaline,  compared  to  50.5%  for  dopamine. 
Noradrenaline was associated with higher hospital mortality 
and diminished 28-day survival. 
 
Discussion 
Both RCTs had consistent findings: the rate of death at 28 days 
was  not  significantly  different  between  dopamine  and 
noradrenaline, but dopamine was associated with increased 
arrhythmic  events.
6,7  The  observational  studies  drew 
conflicting conclusions. The SOAP study concluded dopamine 
was  associated  with  higher  mortality  at  30  days,  while  the 
SACiUCI  study  found  noradrenaline  was  associated  with 
higher mortality at 28 days.
8,9 The strength of the data from 
the observational studies is weaker because of the lack of 
randomisation.  While  a  significant  mortality  difference 
between  dopamine  and  noradrenaline  was  not 
demonstrated, it is important to note that an intention-
to-treat analysis was used in the SOAP II study in 2010. 
This  might  underestimate  any  mortality  difference 
between  dopamine  and  noradrenaline.  Of  note, 
dopamine use in cardiogenic shock increased  mortality, 
compared to noradrenaline.
6  
 
Taken together, the bulk of the data from the literature 
(SOAP II study 2010, Patel et al. study 2010) suggests that 
dopamine is associated with increased arrhythmic events 
compared to noradrenaline, and may even be associated 
with increased mortality.
8 Therefore, it could be argued 
that noradrenaline is the preferred first line vasopressor 
in septic shock. This data challenges the current guideline 
recommendation that dopamine should be one of the two 
first line vasopressor agents in septic shock.   
 
Conclusion 
The  available  data  suggests  that  there  is  no  significant 
difference  in  mortality  at  28  days  between  patients 
treated with dopamine or noradrenaline as the first line 
vasopressor in septic shock. However, results from a small 
number of studies indicate that dopamine is associated 
with  more  arrhythmic  events.  Therefore,  noradrenaline 
may  be  preferred  over  dopamine  as  the  first  line 
vasopressor  in  septic  shock  to  avoid  the  adverse 
cardiovascular events. 
 
Summary of important points 
1. There is no significant mortality difference at 28 days in 
patients  with  septic  shock  treated  with  dopamine  or 
noradrenaline.  
2. Dopamine is associated with more arrhythmic events. 
3.  Noradrenaline  might  be  preferred  over  dopamine  as 
the first line vasopressor to avoid cardiovascular adverse 
events. 
4.  The  recent  SOAP  II  study  challenges  the  guideline 
recommendation  that  dopamine  should  be  one  of  two 
first line vasopressor agents in septic shock. 
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